chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Nausea, Vomiting, Diarrhea      Fever/body aches for 1 week. Tested negative for covid. Continues to have N/V/D with weight loss. She had a kidney transplant.  ? Fever     HPI patient is a 58-year-old female presents to ED for nausea vomiting diarrhea. Patient has a history of chronic kidney disease with a kidney transplant 10 years prior, hypertension, hyperlipidemia, and polycystic liver disease. Patient reports that she's had nausea and vomiting and diarrhea for one week. Patient continues to have worsening symptoms. Patient has had weight loss. Patient was recently tested for COVID which was negative. Patient reports fatigue and feeling weak and dizzy. Patient is unable to tolerate oral intake due to the nausea and vomiting. Patient denies any other complaints including chest pain, shortness of breath, cough, numbness or tingling.
15x6 cm welts and hives on the ventral, mid axilla and deltoid region
Information has been received from a certified medical assistant concerning an unidentified patient who on unspecified date in the past "may" have been vaccinated with a dose of MMR II. It was reported that the patient was negative for mumps antibody. It was noted that the patient did have antibody against measles and rubella. The reporter was not sure of the patient's history and she had not information regarding the patient. Follow up Information was received on 02-FEB-2009 from the certified medical assistant who stated that there was no adverse experience related to the initial report. Additional information has been requested.
COVID-19 resulting in inpatient hospitalization of a vaccinated patient. 3rd Pfizer vaccine given 11/2/2021.
expired vaccine that was punctured past 12 hours; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired vaccine that was punctured past 12 hours) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Sep-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired vaccine that was punctured past 12 hours). At the time of the report, EXPIRED PRODUCT ADMINISTERED (expired vaccine that was punctured past 12 hours) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant and treatment information were reported by the reporter
Patient received Moderna vaccine on 3/12 and passed away on 3/14.  Patient had multiple chronic and acute conditions and was in overall poor health.
pt recv vax 31JUL96 & that afternoon pt was warm & what appeared like a heat rash on face, which later spread to body all over by evening had a sever case of hives @ which time they gave 12mil of DPH;
the day after my second dose of pfizer I felt tired, no other side effects until 7:30pm the night after the second dose I started to experience EXTREME stomach pain, all over my mid section- extreme bloating and a heavy feeling to my mid section it lasted for about 3 hours.. the next 4 days this occurred once a day-no particular time or reason of anything I ate can justify what was happening to me. on the 5th day I ended up in the ER because the pain was unbearable and I began to vomit from the severe pain. It occured 2 more times after my ER visit but not as severely as the ER visit day. I have not experienced any other pain like this for about 3 weeks now. I never had any other symptoms of fever, chills, body aches -NOTHING - just severe pain in my mid section and there was no one spot the pain was occuring it was everywhere in my stomach(it was worse than child labor)
pt recv vax;devel one firm filled vesicle on lt arm;on 6nar96 devel 3 addtl vesicles;7Mar96 hundreds of vesicles on back,chest,groin;had been seen for sore throat;runny nose;T of 99.3 po;TZANCK test  positive for herpes;
Low grade temperature, shaking chills, muscle aches, headache, fatigue, nausea
Difficulty breathing; tight Chest; dizziness; pain; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Difficulty breathing), CHEST DISCOMFORT (tight Chest), DIZZINESS (dizziness) and PAIN (pain) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, the patient experienced DYSPNOEA (Difficulty breathing), CHEST DISCOMFORT (tight Chest), DIZZINESS (dizziness) and PAIN (pain). At the time of the report, DYSPNOEA (Difficulty breathing), CHEST DISCOMFORT (tight Chest), DIZZINESS (dizziness) and PAIN (pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medication reported.
dizziness/light-headed; BP was 98/45, 104/48 and 96/45; This is a spontaneous report from a contactable pharmacist. A 45-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via intramuscular in the left arm on 22Feb2021 (at the age of 45-years-old), as a second dose for COVID-19 immunisation. Medical history included hypothyroidism from an unspecified date. Concomitant medication included levothyroxine 25mcg (MANUFACTURER UNKNOWN) was taken for hypothyroidism within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EL3247) via intramuscular in the left arm on 01Feb2021 (at the age of 45-years-old), as a single dose for Covid-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 22Feb2021 at 19:45, after taking the vaccination shot, the patient complained of dizziness. The patient did not have breakfast and the blood pressure was 98/45 (units unspecified). After having snacks and water, blood pressure was checked and it was 104/48 (units unspecified). Still, she was feeling light-headed at 20:00, soon after at 20:23 blood pressure was 96/45 (units unspecified) and it was reported feeling better. The patient did not receive treatment for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events dizziness/light-headed and BP was 98/45, 104/48 and 96/45 was resolved on an unknown date in 2021. No follow-up attempts are needed. No further information is expected.
Information has been received from a registered nurse concerning a 25 year old female with a history of seizures who on 15-JAN-2007 was vaccinated intramuscularly with a 0.5 ml first dose of Gardasil. On 04-APR-2007 the patient was vaccinated with a second dose of Gardasil. On 10-AUG-2007 the patient was vaccinated third dose of Gardasil (lot #0211U). Concomitant therapy included hormonal contraceptives (unspecified). On 10-AUG-2007 the patient stood up and became "really dizzy", passed out, and had a seizure. The patient reported her boyfriend "slapped her and it helped her come out of the seizure". There were no laboratory or diagnostic tests performed. Unspecified medical attention was sought. At the time of the report the patient had recovered. Upon internal review, seizures was considered to be an other important medical event. Additional information has been requested.
Heart pounding and fluttering; Migraine headache; neck pain; dizziness; head and neck hot to the touch (no fever); eye pain; exhaustion; vertigo; mild nausea; Left temple throbbing and pulsating/headache; Heart pounding; This is a spontaneous report from a contactable consumer (patient).  A 40-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 via an unspecified route of administration, administered in Arm Left on 30Apr2021 16:30 (Batch/Lot Number: ER8736), age at vaccination of 40-years-old, as single dose, for covid-19 immunisation.  The patient medical history was not reported. The patient was not pregnant and was not pregnant at the time of vaccination.    There were no concomitant medications.  The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced migraine headache everyday, neck pain, dizziness, head and neck hot to the touch (no fever), eye pain, exhaustion, some vertigo and mild nausea, left temple throbbing and pulsating, heart pounding an fluttering occasionally, all on 30Apr2021 at 1730. No treatments were give for the events. Facility where the most recent COVID-19 vaccine was administered: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient underwent lab tests and procedures which included sars-cov-2 test negative on 10May2021. The patient had not recovered from the events. Information on the lot/batch number has been requested.
rash at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at the injection site) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     NO medical history information was reported.     On 13-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE RASH (rash at the injection site). At the time of the report, VACCINATION SITE RASH (rash at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Jan-2021 and was forwarded to Moderna on 22-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at the injection site) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     NO medical history information was reported.     On 13-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE RASH (rash at the injection site). At the time of the report, VACCINATION SITE RASH (rash at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.  No treatment details were reported.
Pain at injection site; Redness injection site, upper arm/Injection site/upper arm redness hot to touch; Injection site hotness, upper arm; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 4th August 2021, the patient received the 1st dose of Shingrix .5 ml. In August 2021, 24 hrs after receiving Shingrix, the patient experienced injection site pain, injection site erythema and injection site warmth. In August 2021, the outcome of the injection site pain, injection site erythema and injection site warmth were recovered/resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema and injection site warmth to be related to Shingrix.  Additional details were provided as follows: The case was reported by patient herself. The patient received her first dose of the Shingrix vaccine and 24 hours later she experienced redness and pain and hotness at the injection site.   The patient reported that the injection site and the redness on her upper arm was hot to the touch.   The redness at the injection site spread over 7 days across her upper arm.   The patient reported that all symptoms were resolved after 7 days.   The patient was also unsure if the vaccine was administered intramuscularly or not as the location she received it seemed to be more anterior on her arm. The reporter did not consent to follow-up.
This spontaneous report was received from a healthcare worker referring to multiple unspecified patients of unknown age and gender. No information regarding the patients' medical history, concurrent condition and concomitant medication was provided. On unknown dates, the patients were vaccinated with improperly stored doses of VARIVAX injection, lot # L029467, expiration date 06-AUG-2017; lot # L041204, expiration date 20-Oct-2017; lot # L030160, expiration date 11-AUG-2017; lot # L048468, expiration date 02-DEC-2017, (dose and route of administration were not reported). No adverse effects were reported. Data logger was involved. The vaccine lots were exposed to a temperature of 20 degrees fahrenheit (F), time frame of excursion was reported as 4 days and 15 hours total cumulative time. There was no previous excursions. No product quality complaint (PQC) was reported. This is one of several reports from the same reporter. Additional information has been requested.
vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients); vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients); This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients)) and PRODUCT USE ISSUE (vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients)) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033F51A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Dec-2021 at 9:30 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients)) and PRODUCT USE ISSUE (vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients)). On 02-Dec-2021, EXPIRED PRODUCT ADMINISTERED (vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients)) and PRODUCT USE ISSUE (vial sat out in room temperature more than 24hr and were not discarded/Vial was punctured 22 times (punctured 2additional times for the 2 patients)) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment medication use was not provided by the reporter.  Two Moderna vials were taken out of their refrigerator on 30-Nov-2021 at 09:00 am and punctured. They sat out in room temperature for more than 24 hours and were not discarded as they should have been. They also inadvertently administered two patients doses of the vaccine from expired vials on 02-DEC-2021 administered at 9:30 am. The vials impacted have been discarded. The number of doses/vials was 7.5 mL vial - 1 vial. The date the vial was initially stored in the refrigerator on 29-Nov-2021.   This case was linked to US-MODERNATX, INC.-MOD-2021-404102 (E2B Linked Report).; Sender's Comments:  MODERNATX, INC.-MOD-2021-404102:Same reporter
Sudden onset right arm pain, runny nose, knot at injection site, body aches, fever, shortness of breath, wheezing , sore eyes / eye pain;  weakness, extreme fatigue , chest pain
At the time the vaccine was administered, there was a burning experience by the pt. A 2" hard lump (raised) developed at the site. Pt's arm was swollen and painful for 2 weeks. They symptoms persisted and have slowly improved. There is now a "dent" at the site and the arm is still "sore". Pt is seeing own MD (X 3) for continued evaluation of injection site.
Delayed in return of menstrual cycle (3month and counting). Toke 3-4 months for cycle to return with first and second dose as well.
chills all the following day, felt like I had a fever at one point, exhausted and slept all day, sore all over. It felt like I had the flu. Lasted for about 30 hours.
Very bad back pain tired and diarrhea.  Lasted about 4 days than nothing
Patient received Spikevax vaccine and had adverse reaction at the injection site involving a red blotchy rash and itching that lasted approximately 1 week.
Information has been received from a physician concerning a female patient who was vaccinated with a dose of GARDASIL. The physician reported that the patient became pale and felt lightheaded and dizzy after getting the dose of GARDASIL. No other information was available. The patient recovered. Additional information has been requested.
I had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months/Symptoms resumed 4-5 days after 1 dose vaccine; I had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months/Symptoms resumed 4-5 days after 1 dose vaccine; This is a spontaneous report from a contactable other healthcare professional (Patient). A 58-years-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Batch/Lot Number: ER8727), via an unspecified route of administration, in Left Arm on 22Mar2021 (at the age of 58-years-old) as DOSE 1, SINGLE for covid-19 immunisation.  The patient medical history included sensation of foreign body from 2020 and ongoing I had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months. Was tx'd with steroid course after laryngoscopy Jun2020 with some improvement but not resolved until Dec2020, pharyngitis from 2020 and ongoing I had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months. Was tx'd with steroid course after laryngoscopy Jun2020 with some improvement but not resolved until Dec2020, covid-19 from Mar2020 to an unknown date I had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months. Was tx'd with steroid course after laryngoscopy Jun2020 with some improvement but not resolved until Dec2020, laryngoscopy from Jun2020 to an unknown date I had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months. Was tx'd with steroid course after laryngoscopy Jun2020 with some improvement but not resolved until Dec2020 , steroid therapy from 2020 to an unknown date I had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months. Was tx'd with steroid course after laryngoscopy Jun2020 with some improvement but not resolved until Dec2020, immunisation from an unknown date and unknown if ongoing. The patient concomitant medication in 4 weeks included varicella zoster vaccine rge (cho) (SHINGRIX) taken for immunisation from 20Feb2021 to 20Feb2021. The patient was not diagnosed covid-19, prior vaccination, Since the vaccination, the patient had not been tested for Covid-19, The patient had no known allergies. On 26Mar2021, the patient stated that she had globus pharyngitis after having Covid Mar2020 which lasting approx 9 months. Was tx'd with steroid course after laryngoscopy Jun2020 with some improvement but not resolved until Dec2020. Symptoms resumed 4-5 days after 1 dose vaccine and have not yet resolved. She has not taken 2nd dose and am concerned re pressure to do so for employment/travel even though my antibody screen remained one full year after illness prior to vaccine. The patient underwent lab tests and procedures which included sars-cov-2 antibody test: high my antibody screen remained high one full year after illness prior to vaccine. Outcome of events was not recovered.  Follow-up attempts are completed. No further information is expected.
The following day - fever, soreness and a Hines?s, which was somewhat expected. However as the evening progressed my heart was racing and felt a little shortness of breathe. The next morning that subsided, however since then, simply walking up the stairs has left me winded. Walking in the store has left me winded. I get dizzy easily. Prior to the second shot was running about a mile every other day and walking a mile. I find it difficult to walk for any amount of time.
Family of three individuals, a father and two daughters, approached vaccination table and placed all three forms on table. Vaccinator took the top paper and verified paperwork with individual seated in chair. Individual confirmed identity as a 17-year-old, and vaccination was administered. When the second child sat down, her identity was confirmed on the second sheet of paper presented, of which she stated that that was her sister who had just been vaccinated. The second individual then confirmed that she was the 17- year- old.
Information has been received from a physician concerning a female patient, who on an unspecified date was vaccinated with a dose of GARDASIL (Lot # not reported). The physician stated that the patient developed bronchitis, shortness of breath and possible bronchospasm. The patient said that might have been sick before receiving the vaccination. The patient went to an emergency room and was discharged with antibiotics. At the time of the report, the patient's outcome was unknown. Additional information has been requested.
10 days after receiving  the Moderna Booster shot I began feeling an itch that started on the back of my head and around my neck. On day 11, February 15th I woke up with itchy and sore hives, welts, red rashes and scratch looking marks that would move  around my body randomly from the top of my head, arms, hips, legs, and would last for 30min-1hr.  then disappear and re-appear every few hours. I also was experiencing minor other symptoms including abdomen cramps, indigestion/heartburn, pain in veins/wrist area , trouble sleeping, water retention and bloating as well as mild lethargy. Currently I am still experiencing these hives day 23 after receiving booster and they are much more milder than during the first week of symptoms  but they still continue to appear several times throughout the day.